0.00Open0.00Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover0.00%IV-66.03%PremiumDec 20, 2024Expiry Date6.96Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.55Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Y-mAbs Therapeutics Stock Discussion
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...
No comment yet